NCT00004057View on ClinicalTrials.gov

Paclitaxel Plus L-778,123 in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphomas

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 31, 1998

Primary Completion Date

December 31, 2000

Study Completion Date

December 31, 2000

Conditions
LymphomaUnspecified Adult Solid Tumor, Protocol Specific
Interventions
DRUG

L-778,123

DRUG

paclitaxel

Trial Locations (1)

10021

Memorial Sloan-Kettering Cancer Center, New York

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00004057 - Paclitaxel Plus L-778,123 in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphomas | Biotech Hunter | Biotech Hunter